0001209191-21-020483.txt : 20210315
0001209191-21-020483.hdr.sgml : 20210315
20210315164534
ACCESSION NUMBER: 0001209191-21-020483
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210311
FILED AS OF DATE: 20210315
DATE AS OF CHANGE: 20210315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ordonez Claudia
CENTRAL INDEX KEY: 0001808290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 21742071
MAIL ADDRESS:
STREET 1: C/O KEROS THERAPEUTICS, INC.
STREET 2: 99 HAYDEN AVENUE, SUITE 120, BUILDING E
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-513-8774
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-11
0
0001664710
Keros Therapeutics, Inc.
KROS
0001808290
Ordonez Claudia
C/O KEROS THERAPEUTICS, INC.
99 HAYDEN AVENUE, SUITE 120, BUILDING E
LEXINGTON
MA
02421
0
1
0
0
Chief Medical Officer
Common Stock
2021-03-11
4
M
0
1000
0.48
A
1000
D
Common Stock
2021-03-11
4
S
0
395
64.09
D
605
D
Common Stock
2021-03-11
4
S
0
605
64.86
D
0
D
Employee Stock Option (right to buy)
0.48
2021-03-11
4
M
0
1000
0.00
D
2029-09-18
Common Stock
1000
101211
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.535 to $64.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.59 to $65.48 inclusive.
One-quarter (1/4th) of the shares subject to the option shall vest on September 16, 2020, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
/s/ Keith Regnante, Attorney-in-Fact
2021-03-15